Posted in | News | Nanomaterials | Nanobusiness

Ceres Nanosciences Launches First Release of Nanotrap ESP Particles

Ceres Nanosciences, LLLP, a biotechnology company using its proprietary NanotrapTM capture particle technology to develop diagnostics and research products, announced today that it has launched the first release of NanotrapTM ESP Particles designed to improve complex biofluid sample processing allowing for the detection of low-abundance proteins that would not otherwise be detected.

The NanotrapTM ESP product targets end users working with a variety of sample types that require a more efficient and powerful method of sample preparation for downstream detection and analysis. NanotrapTM ESP Particles improve the sensitivity of any gel electrophoresis protein detection method including silver staining, Coomassie Blue, Western Blotting and mass spectroscopy analysis.

The ability to rapidly harvest multiple proteins and peptides from a single sample makes NanotrapTM ESP particles an ideal tool for researchers interested in rapid sample processing of low abundance proteins or for the discovery of unknown proteins and peptides present in samples containing high-abundance interfering proteins.

The use of this technology for these applications has recently been published by Dr. Lance Liotta and Dr. Emanuel Petricoin in the journals Nano Research and Nano Letters in 2008 and 2009. "Currently, the single largest barrier to biomarker measurement is the inherent lack of sensitivity of most proteomics platforms” said Emanuel Petricoin, Ph. D., co-director of the Center for Applied Proteomics and Molecular Medicine at George Mason University. “The Nanotrap ESP technology provides a powerful new sample preparation approach that tremendously increases the concentration of the biomarker, and greatly aids our own disease biomarker research."

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.